CASI Pharmaceuticals Analyst Ratings
CASI Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/16/2022 | 426.32% | BTIG | $21 → $10 | Maintains | Buy |
| 11/15/2022 | 426.32% | HC Wainwright & Co. | $12 → $10 | Maintains | Buy |
| 08/15/2022 | 531.58% | HC Wainwright & Co. | $3 → $12 | Maintains | Buy |
| 06/03/2022 | 1005.26% | BTIG | $4 → $21 | Maintains | Buy |
| 05/16/2022 | 57.89% | HC Wainwright & Co. | $4 → $3 | Maintains | Buy |
| 05/18/2021 | 110.53% | BTIG | → $4 | Initiates Coverage On | → Buy |
| 05/14/2021 | 110.53% | HC Wainwright & Co. | $3.5 → $4 | Maintains | Buy |
| 04/26/2021 | 100% | Mizuho | → $3.8 | Initiates Coverage On | → Buy |
| 10/23/2020 | 163.16% | Oppenheimer | → $5 | Initiates Coverage On | → Outperform |
| 03/24/2020 | 84.21% | HC Wainwright & Co. | $7 → $3.5 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 11/16/2022 | 426.32% | BTIG | $21 → $10 | 维护 | 买 |
| 11/15/2022 | 426.32% | HC Wainwright公司 | $12 → $10 | 维护 | 买 |
| 08/15/2022 | 531.58% | HC Wainwright公司 | $3 → $12 | 维护 | 买 |
| 06/03/2022 | 1005.26% | BTIG | $4 → $21 | 维护 | 买 |
| 05/16/2022 | 57.89% | HC Wainwright公司 | $4 → $3 | 维护 | 买 |
| 05/18/2021 | 110.53% | BTIG | → $4 | 开始承保 | →购买 |
| 05/14/2021 | 110.53% | HC Wainwright公司 | $3.5 → $4 | 维护 | 买 |
| 04/26/2021 | 100% | 瑞穗 | → $3.8 | 开始承保 | →购买 |
| 10/23/2020 | 163.16% | 奥本海默 | → $5 | 开始承保 | →跑赢大盘 |
| 03/24/2020 | 84.21% | HC Wainwright公司 | $7 → $3.5 | 维护 | 买 |
What is the target price for CASI Pharmaceuticals (CASI)?
CASI制药(CASI)的目标价是多少？
The latest price target for CASI Pharmaceuticals (NASDAQ: CASI) was reported by BTIG on November 16, 2022. The analyst firm set a price target for $10.00 expecting CASI to rise to within 12 months (a possible 426.32% upside). 5 analyst firms have reported ratings in the last year.
卡塔尔国际集团于2022年11月16日报告了CASI制药公司(纳斯达克代码：CASI)的最新目标价。这家分析公司将目标价定为10美元，预计CASI将在12个月内上涨(可能上涨426.32)。去年有5家分析公司公布了评级。
What is the most recent analyst rating for CASI Pharmaceuticals (CASI)?
CASI制药(CASI)的最新分析师评级是多少？
The latest analyst rating for CASI Pharmaceuticals (NASDAQ: CASI) was provided by BTIG, and CASI Pharmaceuticals maintained their buy rating.
纳斯达克(股票代码：CASI)的最新分析师评级由贝莱德提供，CASI制药维持买入评级。
When is the next analyst rating going to be posted or updated for CASI Pharmaceuticals (CASI)?
CASI制药(CASI)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CASI Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CASI Pharmaceuticals was filed on November 16, 2022 so you should expect the next rating to be made available sometime around November 16, 2023.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与CASI制药的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。CASI制药的上一次评级是在2022年11月16日提交的，所以你应该预计下一次评级将在2023年11月16日左右的某个时候公布。
Is the Analyst Rating CASI Pharmaceuticals (CASI) correct?
分析师对CASI制药(CASI)的评级正确吗？
While ratings are subjective and will change, the latest CASI Pharmaceuticals (CASI) rating was a maintained with a price target of $21.00 to $10.00. The current price CASI Pharmaceuticals (CASI) is trading at is $1.90, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的CASI制药(CASI)评级维持不变，目标价在21.00美元至10.00美元之间。CASI制药(CASI)目前的交易价格为1.9美元，超出了分析师的预测区间。
译文内容由第三方软件翻译。